Anhui Huaren Health Pharmaceutical Co., Ltd. (SHE:301408)
China · Delayed Price · Currency is CNY 19.38
+0.15 (0.78%)
At close: Feb 27, 2026
SHE:301408 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 5,077 | 4,454 | 3,723 | 3,202 | 2,269 | 1,886 |
Other Revenue | 77.81 | 77.81 | 74.42 | 60.74 | 69.46 | 45.24 |
| 5,155 | 4,532 | 3,797 | 3,262 | 2,339 | 1,931 | |
Revenue Growth (YoY) | 17.47% | 19.34% | 16.39% | 39.50% | 21.12% | 26.84% |
Cost of Revenue | 3,454 | 3,066 | 2,642 | 2,205 | 1,526 | 1,233 |
Gross Profit | 1,701 | 1,466 | 1,155 | 1,057 | 812.4 | 697.53 |
Selling, General & Admin | 1,329 | 1,190 | 961.8 | 807.26 | 687.3 | 559.56 |
Research & Development | 30.84 | 29.39 | 24.19 | 4.17 | 0.5 | 0.2 |
Other Operating Expenses | 34.66 | 23.07 | 16.64 | 17.16 | 13.02 | 11.42 |
Operating Expenses | 1,397 | 1,243 | 1,005 | 829.62 | 705.21 | 575.75 |
Operating Income | 303.7 | 223.27 | 150.49 | 227.66 | 107.19 | 121.79 |
Interest Expense | -29.25 | -32.15 | -29.05 | -23.38 | -24.03 | -6.8 |
Interest & Investment Income | 14.13 | 17.18 | 14.84 | 5.09 | 2.77 | 3.19 |
Currency Exchange Gain (Loss) | 0.11 | 0.11 | 0.1 | - | - | - |
Other Non Operating Income (Expenses) | -6.61 | -9.29 | -6.79 | -7.74 | -2.73 | -3.05 |
EBT Excluding Unusual Items | 282.08 | 199.12 | 129.58 | 201.63 | 83.21 | 115.11 |
Impairment of Goodwill | -17.2 | -17.2 | - | - | - | - |
Gain (Loss) on Sale of Investments | -0 | - | 0.03 | - | - | - |
Gain (Loss) on Sale of Assets | 3.45 | 2.72 | 1.04 | 0.61 | 0.19 | 0.17 |
Asset Writedown | -6.71 | -0.01 | 0 | -0.01 | -0.02 | 0 |
Other Unusual Items | 17.98 | 20.84 | 20.84 | 12.51 | 10.84 | 7.71 |
Pretax Income | 279.6 | 205.47 | 151.51 | 214.74 | 94.22 | 123 |
Income Tax Expense | 71.82 | 53.21 | 33.83 | 54.48 | 24.48 | 34.14 |
Earnings From Continuing Operations | 207.78 | 152.26 | 117.68 | 160.26 | 69.73 | 88.86 |
Minority Interest in Earnings | -21.29 | -14.56 | -3.01 | 0.52 | -0.01 | 0.06 |
Net Income | 186.5 | 137.7 | 114.67 | 160.78 | 69.73 | 88.92 |
Net Income to Common | 186.5 | 137.7 | 114.67 | 160.78 | 69.73 | 88.92 |
Net Income Growth | 38.58% | 20.09% | -28.68% | 130.58% | -21.58% | 71.17% |
Shares Outstanding (Basic) | 405 | 405 | 395 | 342 | 332 | 342 |
Shares Outstanding (Diluted) | 405 | 405 | 395 | 342 | 332 | 342 |
Shares Change (YoY) | -0.10% | 2.43% | 15.59% | 3.02% | -2.92% | 5.34% |
EPS (Basic) | 0.46 | 0.34 | 0.29 | 0.47 | 0.21 | 0.26 |
EPS (Diluted) | 0.46 | 0.34 | 0.29 | 0.47 | 0.21 | 0.26 |
EPS Growth | 38.72% | 17.24% | -38.30% | 123.81% | -19.23% | 62.50% |
Free Cash Flow | 637.68 | 408.33 | -89.64 | 69.07 | 106.91 | -25.99 |
Free Cash Flow Per Share | 1.57 | 1.01 | -0.23 | 0.20 | 0.32 | -0.08 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | - | - | - |
Gross Margin | 33.00% | 32.34% | 30.43% | 32.41% | 34.74% | 36.13% |
Operating Margin | 5.89% | 4.93% | 3.96% | 6.98% | 4.58% | 6.31% |
Profit Margin | 3.62% | 3.04% | 3.02% | 4.93% | 2.98% | 4.61% |
Free Cash Flow Margin | 12.37% | 9.01% | -2.36% | 2.12% | 4.57% | -1.35% |
EBITDA | 355.6 | 262.12 | 171.93 | 240.37 | 267.85 | 130.21 |
EBITDA Margin | 6.90% | 5.78% | 4.53% | 7.37% | 11.45% | 6.74% |
D&A For EBITDA | 51.9 | 38.85 | 21.45 | 12.71 | 160.66 | 8.43 |
EBIT | 303.7 | 223.27 | 150.49 | 227.66 | 107.19 | 121.79 |
EBIT Margin | 5.89% | 4.93% | 3.96% | 6.98% | 4.58% | 6.31% |
Effective Tax Rate | 25.69% | 25.90% | 22.33% | 25.37% | 25.99% | 27.76% |
Revenue as Reported | 5,155 | 4,532 | 3,797 | 3,262 | 2,339 | 1,931 |
Advertising Expenses | - | 25.19 | 21.36 | 17.99 | 5.27 | 3.93 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.